甲状腺不确定性结节:腺叶切除术与基因检测的成本效果比较
该研究采用Markov决策模型,比较甲状腺腺叶切除术与Afirma®基因检测对Bethesda 3-4不确定性甲状腺结节的成本效果,基础病例为40岁女性1cm结节。结果显示5年内腺叶切除术成本更低且效果更好(6100美元、4.50 QALYs vs 9400美元、4.47 QALYs),仅2.5%模拟中Afirma®在10万美元/QALY阈值下具有净获益。结论提示诊断性腺叶切除术可能占优,但结果对效用值估计高度敏感。
要点
- 对Bethesda 3-4不确定性结节,腺叶切除术在基础病例中成本更低且QALYs更高。
- 仅2.5%模拟中Afirma®在10万美元/QALY阈值下显示净获益。
- 结果对腺叶切除后及Afirma®监测下的效用值估计高度敏感。
核心结论
- 基础病例估计提示诊断性腺叶切除术在排除不确定性甲状腺结节恶性方面优于基因检测策略。
- 结果对腺叶切除后效用值和Afirma®后监测生活的效用值估计高度敏感。
研究设计与样本
- 采用Markov决策模型评估甲状腺腺叶切除术与Afirma®基因检测的成本效果。
- 基础病例为40岁女性,1cm不确定性(Bethesda 3-4)甲状腺结节。
- 概率与效用值来自文献,成本基于Medicare报销,成本和QALYs采用3%贴现率。
主要发现
- 诊断后5年内,腺叶切除术成本6100美元、4.50 QALYs,Afirma®成本9400美元、4.47 QALYs。
- 10000次模拟中仅253次(2.5%)Afirma®在10万美元/QALY阈值下显示净获益。
- Afirma®具有成本节约的概率为0.3%,改善QALYs的概率为14.9%。
临床怎么用
- 在40岁女性1cm Bethesda 3-4结节的基础病例中,诊断性腺叶切除术可能比Afirma®更具成本效果。
- 临床决策需考虑腺叶切除后和Afirma®监测下的效用值估计,因结果对其高度敏感。
局限性
- 结果高度依赖于腺叶切除后效用值和Afirma®后监测生活的效用值估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated whether diagnostic thyroidectomy for indeterminate thyroid nodules would be more cost-effective than genetic testing after including the costs of long-term surveillance. METHODS: We used a Markov decision model to estimate the cost-effectiveness of thyroid lobectomy versus genetic testing (Afirma®) for evaluation of indeterminate (Bethesda 3-4) thyroid nodules. The base case was a 40-year-old woman with a 1-cm indeterminate nodule. Probabilities and estimates of utilities were obtained from the literature. Cost estimates were based on Medicare reimbursements with a 3% discount rate for costs and quality-adjusted life-years. RESULTS: During a 5-year period after the diagnosis of indeterminate thyroid nodules, lobectomy was less costly and more effective than Afirma® (lobectomy: $6,100; 4.50 quality-adjusted life- years vs Afirma®: $9,400; 4.47 quality-adjusted life-years). Only in 253 of 10,000 simulations (2.5%) did Afirma® show a net benefit at a cost-effectiveness threshold of $100,000 per quality- adjusted life-years. There was only a 0.3% probability of Afirma® being cost saving and a 14.9% probability of improving quality-adjusted life-years. CONCLUSIONS: Our base case estimate suggests that diagnostic lobectomy dominates genetic testing as a strategy for ruling out malignancy of indeterminate thyroid nodules. These results, however, were highly sensitive to estimates of utilities after lobectomy and living under surveillance after Afirma®.
引用
- Balentine CJ, Vanness DJ, Schneider DF, et al. Cost-effectiveness of lobectomy versus genetic testing (Afirma®) for indeterminate thyroid nodules: Considering the costs of surveillance. Surgery. 2017. PMID: 29128178. doi:10.1016/j.surg.2017.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。